Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

61.950
-0.150-0.24%
Volume:21.25M
Turnover:1.32B
Market Cap:102.22B
PE:-977.95
High:64.900
Open:64.500
Low:60.850
Close:62.100
Loading ...

Innovent Biologics' Lung Cancer Drug Hets NDA Approval from China's NMPA

MT Newswires Live
·
23 Dec 2024

Innovent Receives Approval of Dovbleron® (Taletrectinib Adipate Capsule, Ros1 Inhibitor) by China's National Medical Products Administration

THOMSON REUTERS
·
20 Dec 2024

BRIEF-Innovent Biologics Says NMPA Approved New Drug Application Of Dovbleron

Reuters
·
20 Dec 2024

Innovent Biologics - Nmpa Approved New Drug Application of Dovbleron (Taletrectinib Adipate Capsule)

THOMSON REUTERS
·
20 Dec 2024

BRIEF-Innovent Biologics Says Lilly To Manage Research And Development And Post-Market Medical Affairs For Jaypirca

Reuters
·
16 Dec 2024

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (Pirtobrutinib) in Mainland China

THOMSON REUTERS
·
16 Dec 2024

Innovent Biologics Inc - Lilly to Manage R&D and Post-Market Medical Affairs for Jaypirca

THOMSON REUTERS
·
16 Dec 2024

Innovent Biologics Inc - to Handle Jaypirca Importation, Marketing, Distribution in China

THOMSON REUTERS
·
16 Dec 2024

Innovent Biologics Grants Options, Restricted Shares Under Incentive Scheme

MT Newswires Live
·
06 Dec 2024

Innovent and HUTCHMED Jointly Announce Nmpa Conditional Approval for Tyvyt® (Sintilimab Injection) in Combination With Elunate® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

THOMSON REUTERS
·
04 Dec 2024

Hutchmed, Іnnovent Biologics Combination Injection Receives Conditional Approval in China

MT Newswires Live
·
03 Dec 2024

BRIEF-Innovent Biologics Updates On New Drug Application For Combination Of Tyvyt And Elunate

Reuters
·
03 Dec 2024

Innovent Biologics - New Drug Application for Combination of Tyvyt and Elunate Granted Conditional Approval in China

THOMSON REUTERS
·
03 Dec 2024

HUTCHMED and Innovent Jointly Announce Nmpa Conditional Approval for Elunate® (Fruquintinib) in Combination With Tyvyt® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

THOMSON REUTERS
·
03 Dec 2024